INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thurs...

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology...

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for C...

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL P...

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update...

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on Marc...

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer...

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORD...

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans...